News | March 26, 2013

European Peripheral Vascular Device Market to Grow Strongly Through 2017

March 26, 2013 — According to two different reports from Millennium Research Group (MRG), the overall European market for peripheral vascular devices will grow strongly, reaching $1.3 billion by 2017. While cost-conscious European healthcare systems will limit selling price increases, peripheral vascular disease (PVD) has been under-diagnosed and undertreated. Increases in endovascular procedures, along with innovations such as drug-coated balloons (DCB), aortic stent grafts and chronic total occlusion (CTO) crossing devices, will support revenue growth.

DCBs have entered the European market only recently. They are starting to increase in popularity, and their adoption will increase significantly after 2015 as reimbursement for the devices spreads across Europe. This will significantly increase market value, as DCBs carry higher selling prices than standard balloons, and also steal some market share from stents, since DCBs are seen as a viable alternative to stenting.

CTOs are blockages that can hinder endovascular treatment because they block access to the treatment site. Physicians are becoming more adept at crossing these occlusions and companies are marketing specialized tools to help, including products from Cordis, Boston Scientific, Avinger, C.R. Bard and Covidien. These devices will contribute to substantial growth in lower-limb endovascular procedures, particularly those in the femoropopliteal and infrapopliteal indications.

Product improvements in the aortic stent graft market, such as those that address the issues of endoleaks, migration and challenging patient anatomies, will boost stent graft adoption in both the abdominal and thoracic aortic indications, making this another significant growth area.

"The growth potential is significant," said MRG analyst Tonya Martin. "The adoption of next-generation abdominal aortic stent grafts will actually expand the treatable patient population. This is true in both the larger markets of Western Europe and in the markets in the Benelux countries, the Nordic region, Spain and Switzerland. Physicians will have the option of performing more endovascular procedures than ever before."

MRG’s European Markets for Peripheral Vascular Devices and European Markets for Peripheral Vascular Devices (Part II) reports include unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, CTO crossing devices, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts, and PV accessory devices sold in France, Germany, Italy and the United Kingdom (Part I) and the Benelux countries (Belgium, Netherlands and Luxembourg), the Nordic region (Sweden, Norway, Finland and Denmark), Spain and Switzerland (Part II).

For more information:

Related Content

Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD) | September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
Overlay Init